Farther Finance Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Farther Finance Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$253	Buy	+108	New	+$229	﹤0.01%	5680
2024 Q3	–	Sell	-85	Closed	-$99	–	4094
2024 Q2	$99	Buy	+85	New	+$100	﹤0.01%	3599

Other funds holding PLX

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

OGF

Orin Green Financial San Diego, California $271M AUM 20.78% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Farther Finance Advisors's PLX Position: Q2 2026 in Review

Farther Finance Advisors opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 108 shares worth $253. The stake represents ﹤0.01% of the portfolio and ranks #5680 among its holdings. This is a return to the name: Farther Finance Advisors previously reported a position in PLX as recently as Q2 2024.

Farther Finance Advisors first reported a position in PLX in Q2 2024 and has held it in 2 quarters since. 7 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Farther Finance Advisors held 108 shares of Protalix BioTherapeutics worth $253 as of Q2 2026.
Protalix BioTherapeutics was a new Farther Finance Advisors position in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5680 holding.
Farther Finance Advisors first reported a position in Protalix BioTherapeutics in Q2 2024 and has held it in 2 quarters since.
7 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.